# Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL)

> **NCT01212380** · PHASE1 · COMPLETED · sponsor: **Ohio State University Comprehensive Cancer Center** · enrollment: 21 (actual)

## Conditions studied

- B-cell Chronic Lymphocytic Leukemia
- Hematopoietic/Lymphoid Cancer
- Prolymphocytic Leukemia
- Recurrent Small Lymphocytic Lymphoma
- Refractory Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** carfilzomib
- **OTHER:** Cytokine Assessment
- **OTHER:** Pharmacodynamic Studies
- **OTHER:** Proteosome Inhibition Assessment
- **OTHER:** Pharmacogenomic Studies

## Key facts

- **NCT ID:** NCT01212380
- **Lead sponsor:** Ohio State University Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2014-07
- **Final completion:** 2015-09
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2016-05-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01212380

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01212380, "Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01212380. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*